Research And Collaboration Agreements (Sanofi To GlaxoSmithKline) (Details) (USD $)
|
12 Months Ended |
0 Months Ended |
1 Months Ended |
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Jul. 20, 2009
|
Jan. 31, 2012
|
Aug. 31, 2012
|
Dec. 31, 2010
|
Jun. 30, 2007
|
Mar. 31, 2006
|
Oct. 31, 2002
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
License and contract revenues |
$ 0exel_LicenseContractandCollaborationReimbursementRevenue |
$ 16,321,000exel_LicenseContractandCollaborationReimbursementRevenue |
$ 47,450,000exel_LicenseContractandCollaborationReimbursementRevenue |
|
|
|
|
|
|
|
Purchase an aggregate shares of common stock |
195,895,769us-gaap_CommonStockSharesIssued |
184,533,651us-gaap_CommonStockSharesIssued |
|
|
|
|
|
|
|
|
Sanofi [Member] |
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
Upfront and milestone payments |
|
|
|
140,000,000.0exel_UpfrontAndMilestonePayments / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
|
|
|
|
|
|
Upfront payment received for license |
|
|
|
120,000,000.0exel_CollaborationAgreementUpfrontPaymentReceivedForLicense / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
|
|
|
|
|
|
Upfront payment received for collaboration |
|
|
|
20,000,000.0exel_CollaborationAgreementUpfrontPaymentReceivedForCollaboration / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
|
|
|
|
|
|
Withholding taxes on upfront payments |
|
|
|
7,000,000exel_CollaborationAgreementWithholdingTaxesOnUpfrontPayments / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
|
|
|
|
|
|
Upfront payments, net of tax |
|
|
|
133,000,000exel_CollaborationAgreementUpfrontPaymentsNetOfTax / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
|
|
|
|
|
|
Maximum amount eligible for development and regulatory milestones |
745,000,000.0exel_MaximumAmountEligibleForDevelopmentAndRegulatoryMilestonesUnderCollaborationsAgreement / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
|
|
|
|
|
|
|
|
|
Proceeds from termination of agreement |
|
|
|
|
15,300,000exel_ProceedsFromTerminationOfAgreement / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
|
|
|
|
|
License and contract revenues |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_SanofiAventisMember |
|
|
|
|
|
|
|
Merck [Member] |
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
Maximum amount eligible for development and regulatory milestones |
239,000,000exel_MaximumAmountEligibleForDevelopmentAndRegulatoryMilestonesUnderCollaborationsAgreement / us-gaap_TypeOfArrangementAxis = exel_MerckMember |
|
|
|
|
|
|
|
|
|
License and contract revenues |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_MerckMember |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_MerckMember |
10,700,000exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_MerckMember |
|
|
|
|
|
|
|
Upfront cash payment |
|
|
|
|
12,000,000exel_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement / us-gaap_TypeOfArrangementAxis = exel_MerckMember |
|
|
|
|
|
Maximum amount eligible for royalties on sales under collaborations agreement |
375,000,000exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement / us-gaap_TypeOfArrangementAxis = exel_MerckMember |
|
|
|
|
|
|
|
|
|
Daiichi Sankyo [Member] |
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
Maximum amount eligible for development and regulatory milestones |
145,000,000exel_MaximumAmountEligibleForDevelopmentAndRegulatoryMilestonesUnderCollaborationsAgreement / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
|
|
|
|
|
|
|
|
|
License and contract revenues |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
5,500,000exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
|
|
|
|
|
|
|
Upfront cash payment |
|
|
|
|
|
|
|
|
20,000,000exel_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
|
Research and development fund |
|
|
|
|
|
|
|
1,500,000.0exel_ResearchAndDevelopmentFund / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
3,800,000exel_ResearchAndDevelopmentFund / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
|
Original research term, years |
|
|
|
|
|
|
|
|
15 months |
|
Extended research term, years |
|
|
|
|
|
|
|
6 months |
|
|
Milestone payment |
|
|
|
|
|
5,500,000.0exel_MilestonePayments / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
5,000,000.0exel_MilestonePayments / us-gaap_TypeOfArrangementAxis = exel_DaiichiSankyoMember |
|
|
|
GlaxoSmithKline [Member] |
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
Upfront and milestone payments |
|
|
|
|
|
|
|
|
|
65,000,000.0exel_UpfrontAndMilestonePayments / us-gaap_TypeOfArrangementAxis = exel_GlaxoSmithKlineMember |
License and contract revenues |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_GlaxoSmithKlineMember |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_GlaxoSmithKlineMember |
0exel_LicenseContractandCollaborationReimbursementRevenue / us-gaap_TypeOfArrangementAxis = exel_GlaxoSmithKlineMember |
|
|
|
|
|
|
|
Research and development funding and loans |
|
|
|
|
|
|
|
|
|
85,000,000.0exel_ResearchAndDevelopmentFundingAndLoan / us-gaap_TypeOfArrangementAxis = exel_GlaxoSmithKlineMember |
Purchase an aggregate shares of common stock |
|
|
|
|
|
|
|
|
|
3,000,000us-gaap_CommonStockSharesIssued / us-gaap_TypeOfArrangementAxis = exel_GlaxoSmithKlineMember |
Royalty expense |
$ 700,000us-gaap_RoyaltyExpense / us-gaap_TypeOfArrangementAxis = exel_GlaxoSmithKlineMember |
$ 400,000us-gaap_RoyaltyExpense / us-gaap_TypeOfArrangementAxis = exel_GlaxoSmithKlineMember |
|
|
|
|
|
|
|
|
GlaxoSmithKline [Member] |
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
Percent of royalty on net sales |
3.00%exel_PercentOfRoyaltyOnNetSale / us-gaap_MajorCustomersAxis = exel_GlaxoSmithKlineMember |
|
|
|
|
|
|
|
|
|